VectivBio Holding AG
NASDAQ:VECT 4:00:00 PM EDT
| Market Cap (Intraday) | 315.21M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $7.68 |
| 50-Day MA | $8.25 |
| 200-Day MA | $6.50 |
VectivBio Holding AG Stock, NASDAQ:VECT
Aeschenvorstadt 36, Basel, Basel-Stadt (Basle Town) 4051
Switzerland
Phone: +41.615.51.30.30
Number of Employees: 32
Description
VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the development of treatments for severe rare conditions with significant unmet medical need. Its product pipeline include Apraglutide and CoMet. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland.